

# Yiangos Yiangou

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8865172/yiangos-yiangou-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

2,588  
citations

21  
h-index

32  
g-index

32  
ext. papers

2,820  
ext. citations

5.2  
avg. IF

4.04  
L-index

#	Paper	IF	Citations
32	Nerve and Vascular Biomarkers in Skin Biopsies Differentiate Painful From Painless Peripheral Neuropathy in Type 2 Diabetes.. <i>Frontiers in Pain Research</i> , <b>2021</b> , 2, 731658	1.4	1
31	Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. <i>Journal of Pain Research</i> , <b>2019</b> , 12, 2039-2052	2.9	31
30	Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization. <i>Pain Reports</i> , <b>2018</b> , 3, e676	3.5	16
29	Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons. <i>PLoS ONE</i> , <b>2018</b> , 13, e0198024	3.7	13
28	Trench Foot or Non-Freezing Cold Injury As a Painful Vaso-Neuropathy: Clinical and Skin Biopsy Assessments. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 514	4.1	13
27	Nociceptin/orphanin FQ receptor expression in clinical pain disorders and functional effects in cultured neurons. <i>Pain</i> , <b>2016</b> , 157, 1960-1969	8	15
26	Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. <i>Molecular Pain</i> , <b>2015</b> , 11, 38	3.4	39
25	Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. <i>Journal of Pain Research</i> , <b>2011</b> , 4, 347-55	2.9	22
24	Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. <i>Gut</i> , <b>2010</b> , 59, 767-74	19.2	152
23	Sensory purinergic receptor P2X3 is elevated in burning mouth syndrome. <i>International Journal of Oral and Maxillofacial Surgery</i> , <b>2010</b> , 39, 815-9	2.9	39
22	Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. <i>Urology</i> , <b>2010</b> , 75, 1514.e15-20	1.6	39
21	Sodium channel Na v 1.7 immunoreactivity in painful human dental pulp and burning mouth syndrome. <i>BMC Neuroscience</i> , <b>2010</b> , 11, 71	3.2	20
20	Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. <i>Pain</i> , <b>2008</b> , 138, 667-680	8	113
19	Expression and function of junctional adhesion molecule-C in myelinated peripheral nerves. <i>Science</i> , <b>2007</b> , 318, 1472-5	33.3	50
18	Voltage-gated ion channel Nav1.7 innervation in patients with idiopathic rectal hypersensitivity and paroxysmal extreme pain disorder (familial rectal pain). <i>Neuroscience Letters</i> , <b>2007</b> , 427, 77-82	3.3	29
17	Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study. <i>BMC Neurology</i> , <b>2006</b> , 6, 1	3.1	56
16	COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. <i>BMC Neurology</i> , <b>2006</b> , 6, 12	3.1	344

15	Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. <i>Journal of Urology</i> , <b>2006</b> , 176, 797-801	2.5	47
14	Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. <i>Journal of Urology</i> , <b>2006</b> , 176, 367-73	2.5	144
13	Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. <i>BMC Urology</i> , <b>2006</b> , 6, 6	2.2	134
12	Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. <i>Pain</i> , <b>2005</b> , 114, 386-396	8	613
11	Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. <i>Urology</i> , <b>2005</b> , 65, 400-5	1.6	159
10	P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. <i>European Urology</i> , <b>2004</b> , 46, 247-53	10.2	137
9	Increased vanilloid receptor VR1 innervation in vulvodynia. <i>European Journal of Pain</i> , <b>2004</b> , 8, 129-33	3.7	127
8	Plasticity of gene expression in injured human dorsal root ganglia revealed by GeneChip oligonucleotide microarrays. <i>Journal of Clinical Neuroscience</i> , <b>2004</b> , 11, 289-99	2.2	15
7	Capsaicin receptor VR1 and ATP purinoceptor P2X3 in painful and nonpainful human tooth pulp. <i>Journal of Orofacial Pain</i> , <b>2003</b> , 17, 245-50		48
6	Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. <i>Journal of the Peripheral Nervous System</i> , <b>2002</b> , 7, 190-7	4.7	34
5	Increased acid-sensing ion channel ASIC-3 in inflamed human intestine. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2001</b> , 13, 891-6	2.2	97
4	Effects of preprovasoactive intestinal polypeptide-derived peptides on ileal output. <i>Gastroenterology</i> , <b>1990</b> , 98, 505-8	13.3	4
3	Comparison of neuromedin-N and neurotensin on net fluid flux across rat small intestine. <i>European Journal of Pharmacology</i> , <b>1990</b> , 175, 43-7	5.3	4
2	Infusion of prepro-VIP derived peptides in man: effect on secretion of prolactin. <i>Neuroendocrinology</i> , <b>1988</b> , 48, 615-8	5.6	14
1	Characterization of a novel prepro VIP derived peptide. <i>Biochemical and Biophysical Research Communications</i> , <b>1986</b> , 139, 1142-9	3.4	19